NCT00929968View on ClinicalTrials.gov

Safety, Tolerability and Pharmacokinetics of Multiple Doses of VAK694 in Atopic Subjects With Seasonal Rhinitis

PHASE2CompletedINTERVENTIONAL
Enrollment

35

Participants

Timeline

Start Date

June 30, 2009

Primary Completion Date

February 28, 2011

Conditions
Allergic Rhinitis
Interventions
BIOLOGICAL

Placebo

BIOLOGICAL

VAK694

DRUG

Fluticasone

Trial Locations (2)

16635

Altoona Center for Clinical Research, Duncansville

Unknown

Novartis Investigative Site, Ottawa

Sponsors
All Listed Sponsors
lead

Novartis Pharmaceuticals

INDUSTRY